24.10.2022 - EQS-News: AiCuris Anti-infective Cures AG / Key word(s): Study results AiCuris’ Licensing Partner MSD Demonstrates Efficacy in Phase 3 Study with PREVYMIS for Prevention of Cytomegalovirus Disease in Adults After Kidney Transplantation 24.10.2022 .
08.04.2022 AiCuris nominates Madam Therapeutics with its innovative peptide approach to fight AMR as the first winner of the AiCubator Resident Status in 2022 | AiCuris Anti-infective Cures AG | News | Nachricht | Mitteilung
09.02.2022 AiCuris and Hybridize Therapeutics enter worldwide license agreement of up to €100M for a direct-acting RNA-based therapy against BK Virus | AiCuris Anti-infective Cures AG | News | Nachricht | Mitteilung
a new class of molecules with a novel resistance-breaking mode of action and the potential to replace common antibiotics Artilysins are able to pass the protective outer membrane of Gram-negative.